This suggests that the relative contribution of amyloid-β pathology to cognitive impairment is limited at more advanced disease stages [29–31] and is presumably driven by other processes including accumulation of tau pathology and cerebrovascular disease. The gene discussed is MAPT; the disease is Cognitive impairment.